Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginseng + regorafenib is a combination therapy being investigated for its potential synergistic effects in cancer treatment. Regorafenib is a kinase inhibitor that targets multiple kinases involved in tumor growth and angiogenesis, while ginseng is an herbal supplement with potential anti-cancer and supportive care properties. The combination has shown synergistic inhibitory effects on cancer cell growth in preclinical studies, particularly in hepatocellular carcinoma (HCC). Clinical research is also exploring whether ginseng can help reduce fatigue and improve adherence to regorafenib treatment in colorectal cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginseng + regorafenib.